Skip to main content

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.

Details of the event are as follows:

Date: Tuesday, December 6, 2022

Time: 9:40 a.m. ET

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.35
-4.68 (-2.11%)
AAPL  256.88
-5.89 (-2.24%)
AMD  228.61
-9.42 (-3.96%)
BAC  50.98
-0.54 (-1.05%)
GOOG  252.45
+1.11 (0.44%)
META  730.23
-3.04 (-0.41%)
MSFT  519.52
+1.87 (0.36%)
NVDA  178.93
-2.23 (-1.23%)
ORCL  274.04
-1.11 (-0.40%)
TSLA  436.41
-6.19 (-1.40%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.